

RETRACTION NOTE

Open Access



Retraction Note: A synthetic dsRNA, as a TLR3 pathway synergist, combined with sorafenib suppresses HCC in vitro and in vivo

Yu-Yin Xu^{1,2†}, Li Chen^{1*†}, Gui-Lan Wang¹, Jia-Ming Zhou¹, Yi-Xin Zhang³, Yin-Ze Wei³, Yuan-Yuan Zhu⁴ and Jing Qin¹

Retraction Note: BMC Cancer 13, 527 (2013)

<https://doi.org/10.1186/1471-2407-13-527>

Published online: 07 July 2023

The Editor has retracted this article because it appears that some of the text and figures have been previously published by some of the same authors. Specifically:

- there is substantial text overlap with results section in [1]
- Figure 2B appears to present the same data as Fig. 1C in [1]
- It appears the same FACS plots have been presented in Fig. 3B (for srfn, poly (I:C) and control) as in Fig. 4A in [1]
- Figure 3C (sifn and Poly(I:C)) and 3D appear to show the same images as those published previously in [1] in Fig. 3A

Author Yu-Yin Xu does not agree to this retraction. None of the other authors have responded to any correspondence from the editor or publisher about this retraction

References

1. Chen, L., Xu, Y., Zhou, J., Wu, Y., E, Q., Zhu, Y. "TLR3 dsRNA agonist inhibits growth and invasion of HepG2.2.15 HCC cells". *Oncology Reports* 28.1 (2012): 200–206.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

[†]Equal contributors.

The online version of the original article can be found at <https://doi.org/10.1186/1471-2407-13-527>

*Correspondence:

Li Chen

bl1@ntu.edu.cn

¹Department of Pathological Anatomy, Nantong University, Nantong, China

²Department of Nephrology, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China

³Department of Pathology, Affiliated Tumor Hospital, Nantong University, Nantong, China

⁴Biomics (Nantong) Co., Ltd, Nantong, China

